Dr. Jeffrey Bednarski, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Acute Myelogenous Leukemia
Studies Childhood Leukemia
6 reported clinical trials
13 drugs studied
Affiliated Hospitals
Clinical Trials Jeffrey Bednarski, M.D., Ph.D. is currently running
Memory-like NK Cells after Haploidentical Transplant
for AML
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.
Recruiting1 award Phase 1 & 212 criteria
Stem Cell Transplant
for Blood Cancer
This single arm pilot phase I study with safety run-in is designed to estimate the safety and efficacy of a familial mismatched or haploidentical hematopoietic stem cell transplantation (haplo-HSCT) using a novel graft modification technique (selective αβ-TCR and CD19 depletion).
Recruiting1 award Phase 1
More about Jeffrey Bednarski, M.D., Ph.D.
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jeffrey Bednarski, M.D., Ph.D. has experience with
- Fludarabine
- Ex Vivo T-cell Receptor Alpha-beta And CD19+ Depletion Using CliniMACs Plus
- Αβ-TCR/CD19 Cell Depleted Haploidentical Hematopoietic Stem Cell Graft
- Alemtuzumab
- Melphalan
- Thiotepa
Breakdown of trials Jeffrey Bednarski, M.D., Ph.D. has run
Acute Myelogenous Leukemia
Childhood Leukemia
Severe Combined Immunodeficiency
Acute Myeloid Leukemia
Immune Dysfunction
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jeffrey Bednarski, M.D., Ph.D. specialize in?
Jeffrey Bednarski, M.D., Ph.D. focuses on Acute Myelogenous Leukemia and Childhood Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved Stage IV patients, or patients who are undergoing treatment.
Is Jeffrey Bednarski, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Jeffrey Bednarski, M.D., Ph.D. is currently recruiting for 3 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Jeffrey Bednarski, M.D., Ph.D. has studied deeply?
Yes, Jeffrey Bednarski, M.D., Ph.D. has studied treatments such as Fludarabine, Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus, αβ-TCR/CD19 cell depleted haploidentical hematopoietic stem cell graft.
What is the best way to schedule an appointment with Jeffrey Bednarski, M.D., Ph.D.?
Apply for one of the trials that Jeffrey Bednarski, M.D., Ph.D. is conducting.
What is the office address of Jeffrey Bednarski, M.D., Ph.D.?
The office of Jeffrey Bednarski, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.